Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate patients > 18 years of age with transfusion-dependent
gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without
concurrent hereditary hemorrhagic telangiectasia (HHT). This study will focus on documented
bleeding sites in the small bowel, including the duodenum, jejunum and ileum. Eligible
patients will have endoscopically-documented sites of vascular ectasia and will have required
at least 4 units of blood transfusion or episodes of intravenous iron administration over the
preceding four months.